A recent study reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a major health publication points out that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People using these drugs must be cognizant of the potential of quick rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to pre-treatment mass in about a year and a half.
Weighing Treatments
The research, which reviewed 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through diet and exercise generally see a slower creep back—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts suggest the way of the jabs accounts for the heightened rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the high risk of relapse, the treatment is often life-long.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have come off the jabs report a intense resurgence of cravings.
"It felt as if a switch flipping and I was suddenly extremely hungry," said an individual.
This challenge is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.
Growing Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on integrated behavioural changes.
